


Stem cell transplant reviewed for peripheral T-cell lymphoma

June 10 2021



(HealthDay)—For patients with refractory or relapsed peripheral T-cell



lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic stem cell transplant (HSCT), but transplant-related mortality (TRM) is higher with allogeneic HSCT, according to a review published online May 27 in *JAMA Network Open*.

Jun Du, M.D., from the Chinese Academy of Medical Sciences and Peking Union Medical College in Tianjin, China, and colleagues conducted a systematic review of the literature and meta-analysis to compare the effectiveness and safety of allogeneic HSCT versus autologous HSCT among patients with R/R-PTCL. Thirty trials were included in the meta-analysis, with 880 and 885 patients undergoing allogeneic and autologous HSCT, respectively.

The researchers found that the three-year OS and PFS were 50 and 42 percent, respectively; five-year OS and PFS were 54 and 48 percent, respectively; and three-year TRM was 32 percent in the allogeneic HSCT group. The three-year OS and PFS were 55 and 41 percent, respectively; five-year OS and PFS were 53 and 40 percent, respectively; and three-year TRM was 7 percent in the autologous HSCT group.

"The data from this meta-analysis provide evidence that for select patients with PTCL, both autologous HSCT and allogeneic HSCT may be a potentially effective approach to treatment," write the authors of an accompanying editorial. "This meta-analysis falls short of providing a rigorous, risk-segmented analysis of which modality is more likely to be most effective for a particular patient."

More information: <u>Abstract/Full Text</u> <u>Editorial</u>

Copyright © 2021 HealthDay. All rights reserved.



Citation: Stem cell transplant reviewed for peripheral T-cell lymphoma (2021, June 10) retrieved 27 April 2024 from

https://medicalxpress.com/news/2021-06-stem-cell-transplant-peripheral-t-cell.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.